Breaking News Instant updates and real-time market news.

GOOG

Alphabet

$1,123.19 /

+65.66 (+6.21%)

, GOOGL

Alphabet Class A

$1,121.00 /

+66.87 (+6.34%)

13:16
03/24/20
03/24
13:16
03/24/20
13:16

Google, LG may forgo Qualcomm's Snapdragon 865 for flagships, Gadgets 360 says

According to Gadgets 360, citing sources, Google (GOOG) and South Korea's Technology giant LG, will probably forgo using the top tier Qualcomm (QCOM) Snapdragon 865 platform this year for their smartphones due to the cost of the processor. " a report claimed. The Pixel 5 and Pixel 5 XL don't actually use Qualcomm's flagship Snapdragon 865 as per the Android code base. Both are running the Snapdragon 765G, a chip that's one step down from the 865 in Qualcomm's lineup. There isn't actually a Snapdragon 865 Google phone in the Android repository," said Gadgets 360, citing an ArsTechnica report. Reference Link

GOOG

Alphabet

$1,123.19 /

+65.66 (+6.21%)

GOOGL

Alphabet Class A

$1,121.00 /

+66.87 (+6.34%)

QCOM

Qualcomm

$63.93 /

+1.36 (+2.17%)

  • 24

    Mar

  • 25

    Mar

  • 25

    Mar

  • 31

    Mar

  • 06

    Apr

  • 20

    Apr

  • 29

    Apr

  • 14

    Sep

GOOG Alphabet
$1,123.19 /

+65.66 (+6.21%)

03/24/20 Wedbush
Microsoft, Alphabet among stocks in Wedbush's Shopping List
03/12/20 Bernstein
Square acquisition likelihood low, PayPal among likely bidders, says Bernstein
03/03/20 Jefferies
Booking, Expedia, TripAdvisor price targets lowered at Jefferies
02/27/20 Morgan Stanley
Morgan Stanley sees opportunities for legacy automakers to take share from Tesla
GOOGL Alphabet Class A
$1,121.00 /

+66.87 (+6.34%)

03/10/20 Loop Capital
Alphabet price target lowered to $1,320 from $1,450 at Loop Capital
03/05/20 BofA
Google Travel business likely to snap back in 2021, says BofA
QCOM Qualcomm
$63.93 /

+1.36 (+2.17%)

03/24/20 Exane BNP Paribas
Qualcomm downgraded to Underperform from Outperform at Exane BNP Paribas
03/19/20 Canaccord
Qualcomm price target lowered to $96 from $115 at Canaccord
03/17/20 Goldman Sachs
Qualcomm price target lowered to $77 from $89 at Goldman Sachs
03/13/20 Nomura Instinet
COVID-19 may create demand risk in semiconductors, says Nomura Instinet

TODAY'S FREE FLY STORIES

Upgrade
Aristocrat Leisure upgraded to Buy from Neutral at Goldman Sachs » 08:46
03/29/20
03/29
08:46
03/29/20
08:46
ARLUF

Aristocrat Leisure

$0.00 /

+ (+0.00%)

Goldman Sachs analyst…

Goldman Sachs analyst Kane Hannan upgraded Aristocrat Leisure to Buy from Neutral with a A$29 price target. There is significant near-term earnings uncertainty in the company's land-based businesses from global casino closures, but the stock's 48% since February is unjustified, Hannan tells investors in a research note. Aristorcat will emerge in a "materially stronger" competitive position, its digital growth is accelerating, and its balance sheet issues are "overplayed," contends the analyst.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Huazhu Group upgraded to Buy from Neutral at Goldman Sachs » 08:43
03/29/20
03/29
08:43
03/29/20
08:43
HTHT

Huazhu Group

$27.81 /

-2.08 (-6.96%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Morgan Stanley economists/strategists to hold analyst/industry conference call » 04:55
03/29/20
03/29
04:55
03/29/20
04:55

US Fixed Income Analyst…

US Fixed Income Analyst Tirupattur, Biotech Analyst Harrison, US Public Policy & Municipal Strategist Zezas, US & European Credit Strategist Sankaran and Chief US Equity Strategist Wilson provide their viewpoints on the opportunities and risks across asset classes on an Analyst/Industry conference call to be held on March 29 at 2 pm.

Conference/Events
Preferred Apartment management to meet with JMP Securities » 04:55
03/29/20
03/29
04:55
03/29/20
04:55
APTS

Preferred Apartment

$7.44 /

-0.22 (-2.87%)

Meetings to be held in…

Meetings to be held in the Midwest March 30-31 hosted by JMP Securities.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Smith Micro participates in a conference call hosted by B. Riley FBR » 04:55
03/29/20
03/29
04:55
03/29/20
04:55
SMSI

Smith Micro

$4.22 /

+ (+0.00%)

Conference call with…

Conference call with management to be held on March 30 hosted by B. Riley FBR.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Upland Software participates in a conference call with Jefferies » 17:02
03/28/20
03/28
17:02
03/28/20
17:02
UPLD

Upland Software

$24.51 /

-1.81 (-6.88%)

Software & Internet…

Software & Internet Analyst Thill holds a conference call with Chairman & CEO McDonald and CFO Hill on April 1 at 10 am hosted by Jefferies.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Jefferies software/Internet analyst to hold an analyst/industry conference call » 16:55
03/28/20
03/28
16:55
03/28/20
16:55

Software and Internet…

Software and Internet Analyst Thill, along with Microsoft Cloud Expert Mary Jo Foley, discusses COVID-19 trends on the industry on an Analyst/Industry conference call to be held on March 31 at 11 am.

Conference/Events
Teck Resources to host conference call » 16:46
03/28/20
03/28
16:46
03/28/20
16:46
TECK

Teck Resources

$6.51 /

-1.025 (-13.61%)

Conference call to…

Conference call to provide the Company's QB2 Project Update and Annual Business Review will be held on April 1 at 1 pm. Webcast Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Sintx Technologies to host business news update conference call » 16:34
03/28/20
03/28
16:34
03/28/20
16:34
SINT

Sintx Technologies

$0.43 /

+0.0922 (+27.29%)

Business news update…

Business news update conference call will be held on April 2 at 11 am. Webcast Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Neonode to host conference call » 16:30
03/28/20
03/28
16:30
03/28/20
16:30
NEON

Neonode

$1.57 /

-0.08 (-4.85%)

Management to hold a…

Management to hold a strategic review conference call on April 2 at 7 am. Webcast Link

Conference/Events
Sanderson Farms to host conference call » 16:21
03/28/20
03/28
16:21
03/28/20
16:21
SAFM

Sanderson Farms

$119.18 /

-5.08 (-4.09%)

Conference call to…

Conference call to provide an update on the Company's response to COVID-19 and current poultry market conditions will be held on April 2 at 11 am. Webcast Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
GM agrees to $120M settlement to resolve ignition lawsuits, Bloomberg says » 12:42
03/28/20
03/28
12:42
03/28/20
12:42
GM

General Motors

$21.37 /

-1.17 (-5.19%)

General Motors agreed to…

General Motors agreed to a $120M settlement over faulty ignition switches that allegedly caused cars to stall and air bags to deploy, in some cases triggering fatal accidents, Bloomberg's Robert Burnson reports. The deal, which must be approved by a judge, would resolve hundreds of lawsuits filed before the automaker sought bankruptcy protection in 2009, the author notes. Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
SoftBank's OneWeb files for bankruptcy, Bloomberg reports » 12:40
03/28/20
03/28
12:40
03/28/20
12:40
SFTBY

SoftBank

$0.00 /

+ (+0.00%)

OneWeb filed for…

OneWeb filed for bankruptcy, becoming one of the first companies backed by SoftBank to seek court protection from its creditors after high costs and stiff competition led to a cash crunch, Bloomberg's Rick Green and Eliza Ronalds-Hannon report. The company listed liabilities and assets of more than $1B each in its Chapter 11 petition in U.S. Bankruptcy Court in White Plains, New York. Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
Ocado buys 100,000 coronavirus testing kits from staff, Telegraph says » 10:59
03/28/20
03/28
10:59
03/28/20
10:59
OCDGF

Ocado Group

$0.00 /

+ (+0.00%)

Ocado has bought 100,000…

Ocado has bought 100,000 coronavirus testing kits to keep as many employees as possible in warehouses and on the road delivering food, The Telegraph's Phoebe Southworth, Tony Diver, Charles Hymas and Jack Hardy report. Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Amgen announces results from Phase 3B study of Repatha » 10:17
03/28/20
03/28
10:17
03/28/20
10:17
AMGN

Amgen

$198.49 /

+ (+0.00%)

Amgen announced positive…

Amgen announced positive results from the EvolocumaB Effect on LDL-C LowerIng in SubJEcts with Human Immunodeficiency ViRus and INcreased Cardiovascular RisK study evaluating the efficacy and safety of Repatha in patients who are human immunodeficiency virus-positive and have high low-density lipoprotein cholesterol despite stable background lipid-lowering therapy. The study demonstrated that treatment with Repatha significantly reduced LDL-C. Results from the double-blind 24-week study show that in people living with HIV with hypercholesterolemia or mixed dyslipidemia, monthly treatment with Repatha reduced LDL-C by 56.9% from baseline compared to placebo, meeting its primary endpoint.1 Patients treated with Repatha also demonstrated improved secondary outcomes versus placebo with 71.9% of patients achieving an LDL-C reduction of more than or equal to 50% from baseline and 65.4% of patients achieving an LDL-C of less than 70 mg/dL. No new safety concerns were identified in the BEIJERINCK trial. The subject incidence of treatment-emergent adverse events was comparable among both groups. The Phase 3b BEIJERINCK study is part of Amgen's PROFICIO program of clinical and real-world evidence studies investigating the impact of Repatha and examining the use of lipid-lowering therapies across different patient populations. To date, the PROFICIO program consists of 35 clinical trials including more than 41,000 patients worldwide and more than 80 real-world evidence studies.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Edwards Lifesciences pauses enrollments in pivotal Mitral, Tricuspid trials » 10:14
03/28/20
03/28
10:14
03/28/20
10:14
EW

Edwards Lifesciences

$198.40 /

-1.49 (-0.75%)

Edwards Lifesciences…

Edwards Lifesciences announced it will temporarily pause new enrollments in its active pivotal clinical trials of transcatheter mitral and tricuspid therapies, in response to the urgent COVID-19 response around the globe. Edwards is coordinating with the trials' clinical investigators, and the decision to resume enrollments in the trials will be made in consultation with each investigator and hospital at the time when their clinicians' and patients' needs can be better served.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Merck presents results from VICTORIA trial evaluating vericiguat » 10:11
03/28/20
03/28
10:11
03/28/20
10:11
MRK

Merck

$71.62 /

-1.77 (-2.41%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

Merck (MRK) announced the…

Merck (MRK) announced the presentation of results from the VICTORIA trial, a Phase 3 study evaluating the efficacy and safety of its investigational drug vericiguat, an orally administered soluble guanylate cyclase stimulator being developed to treat patients with heart failure with reduced ejection fraction and following a worsening event. VICTORIA is the first contemporary outcomes study focused exclusively on symptomatic chronic heart failure patients following a worsening event. Vericiguat is being jointly developed with Bayer (BAYRY). Patients enrolled in VICTORIA were at high risk of hospitalization and cardiovascular death following a recent heart failure decompensation. Vericiguat, when given in combination with available heart failure therapies, met the primary efficacy endpoint of reducing the risk for the composite endpoint of heart failure hospitalization or cardiovascular death in patients with worsening chronic heart failure with reduced ejection fraction, compared to placebo. A hazard ratio of 0.90 in this high risk population translated into a clinically relevant 4.2/100 patient-years absolute reduction in event rate. Based on this absolute risk reduction, the number needed to treat with vericiguat for one year to prevent a primary outcome event is approximately 24 patients. The safety profile of vericiguat was consistent with that reported in previous studies. Merck and Bayer plan to share VICTORIA data with regulatory authorities worldwide.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
AstraZeneca presents new data from sub-analysis of Phase III DAPA-HF trial » 10:08
03/28/20
03/28
10:08
03/28/20
10:08
AZN

AstraZeneca

$42.56 /

+0.26 (+0.61%)

New data from a…

New data from a sub-analysis of the landmark Phase III DAPA-HF trial showed that AstraZeneca's FARXIGA reduced the incidence of the primary composite endpoint of heart failure worsening or cardiovascular death compared to placebo, in patients with heart failure with reduced ejection fraction, irrespective of their background therapy. FARXIGA was evaluated in patients who were receiving a broad range of pharmacological treatments, device therapies and cardiac resynchronization therapy for HFrEF. A consistent reduction in the primary outcome was observed across all these treatment subgroups. FARXIGA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with T2D. In the US it is also approved to reduce the risk of hospitalization for HF in patients with T2D and established CV disease or multiple CV risk factors. In January 2020, the Food and Drug Administration accepted a supplemental New Drug Application and granted Priority Review for FARXIGA to reduce the risk of CV death or the worsening of HF in adults with HFrEF with and without T2D. The Prescription Drug User Fee Act date, the FDA action date for this supplemental application, is scheduled for the second quarter of 2020.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Esperion announces data presentations of NEXLETOL, NEXLIZET Tablet » 09:56
03/28/20
03/28
09:56
03/28/20
09:56
ESPR

Esperion

$35.28 /

-2.07 (-5.54%)

Esperion announced that…

Esperion announced that two pooled analyses from four Phase 3 clinical trials of NEXLETOL and results from the Phase 2 study of NEXLIZET were presented at the American College of Cardiology's 69th Scientific Session Together with World Congress of Cardiology. A poster titled "Bempedoic Acid 180 mg + Ezetimibe 10 mg Fixed Combination Drug Product vs Ezetimibe Alone or Placebo in Patients with Type 2 Diabetes and Hypercholesterolemia" highlighted that in the Phase 2 study, NEXLIZET significantly lowered LDL-Cholesterol by a mean 40% compared to placebo, reduced high-sensitivity C-reactive protein by 25% compared to baseline and resulted in no worsening of glycemic control. The incidence of adverse events rates were generally comparable to placebo. In addition, a poster, titled "Factors Influencing Bempedoic Acid-Mediated Reductions in High-sensitivity C-reactive Protein: Analysis of Pooled Patient-level Data from 4 Phase 3 Clinical Trials" highlighted that in the pooled Phase 3 studies, NEXLETOL significantly lowered hsCRP in patients with hypercholesterolemia regardless of the presence or intensity of background statin therapy. In patients whose hsCRP levels were greater than 2 mg/L at baseline, the analysis showed NEXLETOL significantly reduced this marker of inflammation by 42% at 12 weeks. The third poster was titled "Bempedoic Acid Efficacy and Safety in Patients at High Risk for CVD Treated with or Without Ezetimibe: Pooled Analysis of 4 Phase 3 Clinical Trials" and the pooled analysis showed that in the Phase 3 studies, NEXLETOL provided significant additional LDL-C lowering as well as significantly lowered other lipid endpoints, regardless of the presence of background ezetimibe. Importantly, the safety profile of NEXLETOL was similar with or without background ezetimibe therapy.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Orica upgraded to Buy from Sell at Goldman Sachs » 09:51
03/28/20
03/28
09:51
03/28/20
09:51
OCLDY

Orica

$0.00 /

+ (+0.00%)

Goldman Sachs analyst…

Goldman Sachs analyst Alex Karpos double upgraded Orica to Buy from Sell with a A$20.10 price target. The analyst is more positive on mine production versus "capex-tied earnings" in the current environment and views the recent selloff in the stock as an attractive entry point.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Goldman adds Austal to ANZ Conviction List with 31% potential upside » 09:48
03/28/20
03/28
09:48
03/28/20
09:48
AUTLF

Austal

$0.00 /

+ (+0.00%)

Goldman Sachs analyst…

Goldman Sachs analyst Alex Karpos added Austal to Goldman's ANZ Conviction List with 31% upside to the firm's unchanged price target of A$3.73. The analyst keeps a Buy rating on the shares. Austal is among the more defensive Australia Engineering & Construction stocks with minimal customer risk, long-duration earnings visibility, and a strong balance sheet, Karpos tells investors in a research note.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Redwood Trust delays payment for previously declared 32c dividend » 08:03
03/28/20
03/28
08:03
03/28/20
08:03
RWT

Redwood Trust

$6.22 /

+0.05 (+0.81%)

Redwood Trust announced…

Redwood Trust announced that it has delayed the payment date for its previously declared 32c per share common stock dividend for the first quarter of 2020. The first quarter 2020 dividend is now scheduled to be paid on June 12, 2020. As previously announced on February 27, 2020, the first quarter 2020 dividend will continue to be payable to stockholders of record on March 16, 2020. Christopher Abate, Chief Executive Officer of Redwood Trust, explained, "We remain focused on paying the first quarter dividend. While the decision to delay the payment of this dividend was difficult to make, we believe it is in the best interests of Redwood during this period of near-term uncertainty and volatility caused by the COVID-19 pandemic."

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
Merck, Intel among stocks multifactor-screened for extra safety, Barron's says » 07:23
03/28/20
03/28
07:23
03/28/20
07:23
CAT

Caterpillar

$105.20 /

-5.49 (-4.96%)

, MRK

Merck

$71.62 /

-1.77 (-2.41%)

, UNH

UnitedHealth

$241.80 /

-12.62 (-4.96%)

, INTC

Intel

$52.35 /

-3.26 (-5.86%)

, HON

Honeywell

$131.13 /

-6.095 (-4.44%)

, BBY

Best Buy

$62.36 /

-0.69 (-1.09%)

, GWW

Grainger

$246.57 /

+1.17 (+0.48%)

, DHI

D.R. Horton

$36.79 /

-2.58 (-6.55%)

, QCOM

Qualcomm

$66.50 /

-2.48 (-3.60%)

, AKAM

Akamai

$90.45 /

-4.05 (-4.29%)

, LMT

Lockheed Martin

$348.48 /

-1.96 (-0.56%)

, BLK

BlackRock

$434.59 /

-17.24 (-3.82%)

The financial markets are…

The financial markets are reeling and slammed by generational volatility, many stocks look like bargains, Al Root writes in this week's edition of Barron's. Picking winners and losers in this environment might feel like a fool's errand and starting to sort through the sea of opportunity is a wise idea, the author argues, adding that investors should embrace the power of the stock screen to find names with the right mix of factors for this moment. His final 12 include Caterpillar (CAT), Merck (MRK), UnitedHealth (UNH), Intel (INTC), Honeywell International (HON), Best Buy (BBY), W.W. Grainger (GWW), D.R. Horton (DHI), Qualcomm (QCOM), Akamai Technologies (AKAM), Lockheed Martin (LMT), and BlackRock (BLK). Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
Still value in Softbank stock, Barron's says » 07:07
03/28/20
03/28
07:07
03/28/20
07:07
SFTBY

SoftBank

$0.00 /

+ (+0.00%)

The coronavirus pandemic…

The coronavirus pandemic has further complicated matters for Softbank, pushing its market cap 70% below its asset value, and the company announced a plan to sell $41B of assets over the next 12 months and use $18B of the proceeds to buy back stock, on top of its existing $4.8B buyback, Eric Savitz writes in this week's edition of Barron's. At $35, Softbank's stock still sits at a 66% discount to its assets, the author notes, adding that the company has holdings worth almost triple its current stock price. Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Periodicals
Apple, Amazon to come out of downturn strong, Barron's says » 07:02
03/28/20
03/28
07:02
03/28/20
07:02
GOOG

Alphabet

$1,110.80 /

-50.63 (-4.36%)

, GOOGL

Alphabet Class A

$1,109.46 /

-53.25 (-4.58%)

, AMZN

Amazon.com

$1,900.79 /

-52.4 (-2.68%)

, AAPL

Apple

$247.74 /

-10.74 (-4.16%)

, MSFT

Microsoft

$149.66 /

-6.35 (-4.07%)

Microsoft (MSFT), Apple…

Microsoft (MSFT), Apple (AAPL), Amazon.com (AMZN), and Google parent Alphabet (GOOGL) with their fortress-solid balance sheets, are poised to come out of the downturn just as strong as they went in, Eric Savitz writes in this week's edition of Barron's. Reference Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.